Skip to main content
. 2021 Dec 21;23(1):28. doi: 10.3390/ijms23010028

Figure 6.

Figure 6

The effect of administration of JAK inhibitors in the KCASP1Tg mice. KCASP1Tg mice were treated with baricitinib or cerdulatinib (baricitinib and cerdulatinib, respectively). The clinical phenotype was ameliorated by both JAK inhibitors (a). Plasma Alb levels were measured from 10 to 16 weeks of age. Plasma Alb was recovered in baricitinib- and cerdulatinib-treated mice (b). At 16 weeks of age, the stomach, small intestine, and large intestine were collected and stained with Congo red. Amyloid deposition was reduced in the gastric mucosa and intestinal epithelial cells of the baricitinib- and cerdulatinib-treated KCASP1Tg mice compared with those of the non-treated KCASP1Tg mice (c). Scale bar = 100 μm. * p < 0.05, ** p < 0.01, *** p < 0.001 compared to KCASP1Tg mice by Kruskal–Wallis test.